Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Currency in GBP	2025
Operating Income	-32.96 Million
Income Before Tax	-31.94 Million
Income Tax Expense	-1.29 Million
Net Income	-30.13 Million
Eps	-0.27
Epsdiluted	-0.27
Weighted Average Shs Out	111.92 Million
Weighted Average Shs Out Dil	111.92 Million
Depreciation And Amortization	19.84 Million
Interest Expense	14.50 Million
Ebit	-17.43 Million
Interest Income	5.18 Million
Net Interest Income	-9.32 Million
Period	FY
Ebitda	-13.11 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

Oxford Biomedica plc Annual Reports (10-K)